logo

Compugen Ltd (CGEN)



Trade CGEN now with
  Date
  Headline
12/6/2022 7:08:35 AM Compugen's COM701 Combination Shows Durable Anti-Tumor Activity &Immune Activation In Platinum Resistant Ovarian Cancer
12/1/2022 7:06:58 AM Compugen' COM701 Combination Shows Anti-tumor Activity &immune Activation In Platinum Resistant Ovarian Cancer Patients
11/16/2022 7:19:03 AM Compugen To Get Milestone Payment Of $7.5 Mln From AstraZeneca Phase 2 Initiation Of ARTEMIDE Study
11/14/2022 7:14:17 AM Compugen Q3 Net Loss $11.7 Mln Or $0.14/shr Vs Net Loss Of $6.2 Mln Or $0.07/shr Prior Year
9/22/2022 7:09:18 AM Compugen Issues Letter To Shareholders; Says On Track To Present New COM701/nivolumab MSS-CRC Data In Q4
9/12/2022 7:04:25 AM Compugen Appoints Alberto Sessa As CFO
8/24/2022 7:05:56 AM Compugen Expands Anti-PVRIG COM701 Patent Portfolio With New Composition Of Matter And Use Patent In Japan
8/4/2022 7:48:41 AM Compugen Q2 Net Loss Flat At $9.1 Mln Or $0.11/shr
5/16/2022 7:19:28 AM Compugen Q1 Net Loss $9.7 Mln Or $0.11/Shr Vs $9.9 Mln Or $0.12/Shr Last Year
5/10/2022 7:08:18 AM Compugen CFO And COO Ari Krashin To Step Down
3/9/2022 7:03:26 AM Compugen Presents Research Suggesting Targeting DNAM-1 Axis Holds Promise For Treatment Of Multiple Myeloma
2/24/2022 7:06:58 AM Compugen Q4 Net Loss $8.6 Mln Or $0.10/shr, Same As Last Year